Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 First Quarter Financi... ( HOUSTON Aug. 4 /- C...)

Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 First Quarter Financial Results

Date:8/4/2009

HOUSTON, Aug. 4 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that the company will report financial results for the first quarter ended July 24, 2009 of its fiscal year ending April 30, 2010 on Wednesday, August 19, 2009 at 5:00 PM EDT. The company will conduct a conference call to discuss those results on Thursday, August 20, 2009 at 9:00 AM EDT.

Fiscal Year 2010 First Quarter Results Conference Call Instructions

To listen to the conference call live by telephone dial 877-313-8035 (if dialing from within the U.S.) or 706-679-4838 (if dialing from outside the U.S.). The conference ID is 21678611. Presentation slides will be available on-line at www.cyberonics.com no later than 8:00 AM EDT on Thursday, August 20, 2009. A replay of the conference call will be available approximately two hours after the completion of the conference call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing outside the U.S.). The replay conference ID access code is 21678611. The replay will be available for one week on the above number, and subsequently on the company's website for a period of six months.

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (NASDAQ: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets wor
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan
2. Cyberonics Names Bryan D. Olin, Ph.D. Vice President, Quality
3. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results
4. Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter
5. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results
6. Cyberonics Names Milton M. Morris, Ph.D. Vice President, Research & Development
7. Cyberonics to Present at Piper Jaffray 20th Annual Health Care Conference
8. Cyberonics Reports Strong Sales Growth and Profitability in Fiscal 2009 Second Quarter
9. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results
10. Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS
11. Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike

Post Your Comments:

(Date:12/5/2009)WASHINGTON, Dec. 5 ,, What: Cuts for a Cause ,, Why: To make a difference in the fight against cancer and other terminal illnesses affecting children. All proceeds from each hair service given

(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int

(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for

(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W

(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s

[0] Salon Leau to Host 'Cuts for a Cause' to Raise Funds and Spread the Word About Childhood Terminal Illnesses [0] Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders [0] Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification [0] Distributor Announces New Applications for Wind Turbines [0] KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children

...daq: XTNT ) today reported financial results for ...7., The company reported a net loss and net loss ...on, or $0.52 per share, for the fourth quarter,of ...mpany,s net loss per share attributable to common ...

... same results, analysis shows , , TUESDAY,...cular advantage to any single treatment for acute ...ion that carries with it a high risk of death, Can...or another, according to a report in the Feb. 20 ...

... way to spot hearing problems, study finds, , ...s may not just be a window to the soul, they may a...r senses. , A new study reports that the eyes can ... young children and in people who can,t actively t...

...tive isotopes for peacetime uses at Oak Ridge Nati...al Historic Chemical Landmark by the American Chem...enn., on March 6. , Bruce E. Bursten, Ph.D., pre...s, which began in 1946, demonstrated the peaceful ...

... Hospital, WALLA WALLA, Wash., Feb. 19 Secretary...today the Department of,Veterans Affairs (VA) will...on facility focused on mental health at the Walla ...ortance of mental,health as an issue for our veter...

...ered physical or sexual abuse as children spend up...ts, according to a long-term study of more than 3,...these women used health services at significantly ...quences from abuse that occurred decades ago, said...

Other Medicine News:Health News:XTENT Announces 2007 Financial Results 2 Health News:XTENT Announces 2007 Financial Results 3 Health News:XTENT Announces 2007 Financial Results 4 Health News:XTENT Announces 2007 Financial Results 5 Health News:XTENT Announces 2007 Financial Results 6 Health News:No Difference Found in Treatments for Acute Kidney Failure 2 Health News:No Difference Found in Treatments for Acute Kidney Failure 3 Health News:Eyes a Window to Hearing Loss? 2 Health News:Eyes a Window to Hearing Loss? 3 Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 2 Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 3 Health News:Women who suffered child abuse spend more on health care 2 Health News:Women who suffered child abuse spend more on health care 3

XTENT Announces 2007 Financial Results No Difference Found in Treatments for Acute Kidney Failure Eyes a Window to Hearing Loss?Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark VA Secretary Announces New Walla Walla Facility Women who suffered child abuse spend more on health care

(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab

(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,

(Date:12/3/2009)SAN DIEGO, Dec. 3 BioMed Realty Trust, Inc. (NYSE: BMR ) announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square

Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8 US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9 Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2 Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3 BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2 BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3 AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 1 AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 2 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 1 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 2 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 3 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 4 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 5 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 6 Shire Announces Publication of Open Label Study on Coadministration of INTUNIV 28TM 29 28guanfacine 29 Extended Release Tablets with Stimulants 6285 7 Child Food Allergies on the Rise in U S 61410 1 Child Food Allergies on the Rise in U S 61410 2 Child Food Allergies on the Rise in U S 61410 3

[0] US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder [0] Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects [0] BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark

...nificant Reduction in Relapse Rate , , - Secondar... of Patients Relapse-Free and Disability Progressi...e Tablets Planned for mid-2009 , , SEATTLE and GE...KGaA, announced today detailed results of the two-... III trial using Cladribine Tablets (Merck Serono,...

...y and safety for extended release and immediate re...ril 29 /PRNewswire/ -- New findings from two dou...ty and tolerability of pramipexole dihydrochloride...ation, for the treatment of Parkinson,s disease (P...emy of Neurology (AAN) 61st Annual Meeting in Seat...

Other Medicine Technology:Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 2 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 3 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 4 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 5 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 6 Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis 7 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 2 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 3 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 4 New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting 5

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting

Full Body Girdle V-1655

Body Suit w/Bra above knee, Front Closure

Compression Vest V-640

Male Compression Vest Binder

Medicine Products:

Full Body Girdle V-1655 Body Suit w/Bra above knee, Front Closure Compression Vest V-640 Male Compression Vest Binder

Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 First Quarter Financi...( HOUSTON Aug. 4 /- C...),Health